Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATTERHORN
2023-507338-26-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Durvalumab arm with Placebo arm (2 arms). Primary endpoint: Event-free survival (EFS). Planned start Jan 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-507338-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507338-26-00.